文献速递中医内科中药与中成药合理使用

泽漆汤通过p53通路抑制非小细胞肺癌细胞生长

Traditional Chinese medicine Ze-Qi-Tang formula inhibit growth of non-small-cell lung cancer cells through the p53 pathway.
PubMed 文献 · J Ethnopharmacol · 2019-01-17

泽漆汤(ZQT)是经典中药复方,既往用于咳嗽、哮喘、胸腔积液和肺癌。本研究在A549和H460非小细胞肺癌(NSCLC)细胞及A549裸鼠移植瘤模型中探讨ZQT的分子机制。结果显示ZQT以剂量和时间依赖方式抑制NSCLC细胞增殖并诱导G0/G1期阻滞,该作用与上调p53、下调Cyclin B1和Cdk2相关,且可被pifithrin-a逆转;体内实验显示ZQT抑制肿瘤生长并延长生存,未见肝、肾、心毒性。

要点

  • ZQT以剂量和时间依赖方式抑制A549和H460细胞增殖并诱导G0/G1期阻滞。
  • ZQT诱导凋亡和周期阻滞与上调p53、下调Cyclin B1和Cdk2相关,可被pifithrin-a逆转。
  • 体内实验显示ZQT抑制A549移植瘤生长并延长生存,未见肝、肾、心毒性。

核心结论

  • 泽漆汤抑制非小细胞肺癌细胞生长,是肺癌补充和替代治疗的潜在药物。

研究设计与样本

  • 体外采用A549和H460非小细胞肺癌细胞系,用CCK-8和集落形成实验检测细胞生长,用流式细胞术(annexin V/碘化丙啶、Hoechst 33342或TUNEL染色)检测凋亡或细胞周期阻滞,用western blot检测周期和凋亡相关标志蛋白。
  • 部分实验在ZQT处理前用pifithrin-a阻断NSCLC(A549和H460)细胞的p53活性。
  • 体内采用皮下接种A549细胞诱导肿瘤的裸鼠模型,灌胃给予ZQT(100 mg/kg、200 mg/kg、400 mg/kg)30天,每周测量体重和肿瘤体积,记录生存曲线,用TUNEL检测组织凋亡,用H&E染色检测肝、肾、心病理组织学,用ELISA检测其功能。

主要发现

  • ZQT以剂量和时间依赖方式抑制NSCLC(A549和H460)细胞增殖,并诱导细胞周期阻滞于G0/G1期。
  • 细胞周期阻滞和增殖抑制与p53上调及Cyclin B1和Cdk2下调相关,提示ZQT经线粒体相关途径诱导凋亡。
  • pifithrin-a预处理可逆转ZQT诱导的凋亡和G0/G1期阻滞。
  • ZQT在裸鼠移植瘤模型中抑制肿瘤生长并延长生存。
  • ZQT治疗小鼠未检测到肝、肾或心脏毒性。

临床怎么用

  • ZQT可作为NSCLC的潜在补充和替代治疗药物,其作用与p53通路相关。
  • ZQT在裸鼠模型中未见肝、肾、心毒性,提示安全性较好。

局限性

  • ZQT抗NSCLC活性此前未研究,本研究为首次探讨其分子机制。
  • 研究仅使用A549和H460细胞系及A549裸鼠移植瘤模型,未涉及其他NSCLC模型或临床研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ETHNOPHARMACOLOGICAL RELEVANCE: Ze-Qi-Tang (ZQT), a classic Chinese herbal formula, has been for over thousand years used for the treatment of several respiratory ailments like cough, asthma, hydrothorax and lung cancer. AIM OF STUDY: Cumulative literature on ZQT herbal formula reveals that its several constituent components are potent inducer of apoptosis in different cancer cells. However, the activity of ZQT against non-small-cell-lung cancer (NSCLC) has not been previously examined. The aim of the study is to investigate the molecular mechanism of ZQT on NSCLC cells. MATERIALS AND METHODS: Cell growth were determined by CCK-8 and colony formation assay. Induction of cellular apoptosis or arrest of cell cycle were determined by flow cytometric analysis using annexin V/ propidium iodide, Hoechst 33342 or TUNEL staining method. In some assay p53 activity of NSCLC ( A549 and H460) cells were blocked with pifithrin-a, prior to treatment with ZQT. The level of expression of cell cycle and apoptosis related marker proteins were estimated by western blot. The anticancer activity of ZQT in vivo were monitored in nude mice that were induced with tumor by subcutaneous inoculation of A549 cells and then treated by ZQT(100 mg/kg,200 mg/kg,400 mg/kg) gavaging for 30 days. Mice' body weight and tumor volume were measured weekly. The survival carve was recorded. Apoptosis from mice' tissue was observed by TUNEL assay. Pathological histology of liver, kidney and heart were detected by H&E staining, and its functions were tested by ELISA. RESULTS: Dose- and time-dependent inhibition of proliferation of NSCLC ( A549 and H460) cells by ZQT therapy along with induction of cell cycle arrest at G0⁄G1 phase were observed. The arrest of cell cycle arrest and inhibition of cellular proliferation were associated with up regulation of p53 along with down regulation of Cyclin B1 and Cdk2 indicating a mitochondrial related induction of apoptosis with ZQT. A reversal of ZQT-induced apoptosis and G0⁄G1 arrest was observed with pifithrin-a pretreatment. ZQT was also found to suppress the progression of tumor growth in mouse xenograft models and prolong survival. In addition, no hepato- or nephro- or cardio-toxicity with ZQT treatment were detected in mice. CONCLUSION: These findings suggest that the ZQT formula inhibits the growth of NSCLC cells and is a potential agent of complementary and alternative treatment for lung cancer.

来源:J Ethnopharmacol,查看原文。版权归原作者所有。

引用

  1. Xu Z, Zhang F, Zhu Y, et al. Traditional Chinese medicine Ze-Qi-Tang formula inhibit growth of non-small-cell lung cancer cells through the p53 pathway. J Ethnopharmacol. 2019. PMID: 30660711. doi:10.1016/j.jep.2019.01.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。